



Kansas City District
8050 Marshall Drive, Suite 205
Lenexa, KS 66214

Telephone: (913) 495-5100
FAX: (913) 495-5115

November 18, 2016

Dena K. Perry, President
Perry Drug, Inc.
12200 W 106th St. Ste 140
Overland Park, KS 66215-2305

Dear Ms. Perry:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Perry Drug, Inc. located at 12200 W 106th St., Suite 140, Overland Park, KS 66215-2305, from November 10, 2015, to November 13, 2015, by the U.S. Food and Drug Administration (FDA).


This letter is not intended as an endorsement or certification of your facility. It remains your responsibility to assure compliance with the requirements of federal law, including FDA regulations.

When the Agency concludes that an inspection is "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Ms. Amy Devine at (913) 495-5147 or via email at amy.devine@fda.hhs.gov.

Sincerely,


for Cheryl A. Bigham
Kansas City District Director

Enclosure: EIR